Weng W-K et al. (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 22: 4717–4724
A recent study by Weng and co-workers has investigated the effects of idiotype (Id) vaccination in lymphoma patients. This approach is based on custom vaccines derived from a patient's own tumor.
The study included 136 patients with follicular lymphoma who received Id vaccination following chemotherapy. The patients' humoral immune response to the vaccine was assessed by comparing the anti-Id titer in postvaccine and prevaccine serum samples. T-cell proliferation assays were used to assess the cellular immune response. In addition, the investigators carried out immunoglobulin G Fc receptor (FcγR) genotyping, to assess the predictive value of FcγR polymorphism.
An idiotype-specific humoral immune response was detected in 48 (35%) patients; progression-free survival (PFS) after the last chemotherapy dose was significantly longer in these patients than in those who did not develop anti-Id antibodies. PFS was also longer in patients with FcγRIIIa 158 valine/valine genotype than in those with heterozygous valine/phenylalanine or homozygous phenylalanine/phenylalanine genotypes. Multivariate analysis showed that humoral immune responses and valine/valine genotype were both independent positive predictors for longer PFS. Surprisingly, a cellular immune response, detected in a fifth of all patients, showed no relationship with clinical outcome.
Weng et al. conclude that a humoral immune response to idiotype vaccination is beneficial, and that the antitumor effect is mediated by FcγR-bearing cells. They note that the efficacy of this therapeutic approach might be improved, therefore, by enhancing the antibody response.
Rights and permissions
About this article
Cite this article
Tumor antigen vaccines in follicular lymphoma. Nat Rev Clin Oncol 2, 119 (2005). https://doi.org/10.1038/ncponc0115
Issue Date:
DOI: https://doi.org/10.1038/ncponc0115